IMMUNOHISTOCHEMISTRY, PROSTATE SPECIFIC ANTIGEN (PSA)

The IHC – Prostate Specific Antigen (PSA) test is an immunohistochemistry-based diagnostic assay used to detect PSA protein expression in tissue samples. PSA is a protein produced primarily by cells of the prostate gland and is widely used as an important marker in the diagnosis and evaluation of prostate-related diseases.

This test is especially valuable in pathology for confirming the prostatic origin of tumor cells, particularly in cases of suspected prostate adenocarcinoma or metastatic cancer involving other organs. IHC PSA staining helps pathologists differentiate prostate cancer from non-prostatic tumors and supports accurate cancer classification.

Benefits of the Test

• Helps diagnose prostate cancer
• Confirms prostatic origin of tumor cells
• Assists in identifying metastatic prostate carcinoma
• Supports accurate tumor classification
• Helps guide oncology treatment planning

Why Doctors Recommend This Test

Doctors recommend the IHC PSA test when there is suspicion of prostate cancer or metastatic tumors originating from the prostate gland. It is commonly used in:

• Diagnosis of prostate adenocarcinoma
• Evaluation of metastatic tumors of unknown origin
• Prostate biopsy interpretation
• Cancer staging and pathology studies
• Differentiation of prostate tumors from other malignancies

PSA immunostaining is often used along with other prostate markers such as PSAP, NKX3.1, and AMACR for improved diagnostic accuracy.

Preparation Before Test

No special preparation is required from the patient. Important points include:

• The test is performed on a biopsy or surgical tissue sample
• No fasting or medication restrictions are needed for the IHC test
• Clinical history, serum PSA levels, and imaging findings may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

• Patients with suspected prostate cancer
• Individuals with abnormal prostate biopsy findings
• Cases of metastatic tumors requiring origin confirmation
• Patients undergoing prostate tumor evaluation
• Oncology patients requiring immunohistochemistry profiling

The IHC PSA test is an essential tool in modern oncopathology and urological pathology. By identifying PSA expression in tissue samples, it helps clinicians accurately diagnose prostate cancer and determine the origin of metastatic tumors for appropriate treatment planning.